GSK

2

Jonathan Davitte

OFHS230105

This research aim will be to use genetic and health data to develop new medicines for patients across many diseases. The research will use these data to better understand the causes of disease, what happens after a person has a disease, and how new medicines can improve their health and quality of life. The results will help GSK speed up the development of new medicines, the safety of new medicines, and the impact these medicines have on patients' lives. Individual genetic differences can lead to increased risk for developing disease, poorer disease outcomes, or additional side-effects of disease. These naturally-occurring genetic differences can greatly improve the discovery and development of new medicines. Drugs that have supporting research based on these genetic differences are more than twice as likely to be approved and delivered to patients in need. This allows GSK drug discovery and development resources to focus on researching and delivering medicines that are more likely to succeed in clinical practice. This means new medicines, more effective medicines, and safer medicines for patients across many diseases.

GSK is actively discovering and developing new medicines to benefit patients across many common and rare diseases. The amount of genetic and health data made available through OFH allows GSK to not only identify new drugs that are improvements compared to existing medicines, but also to discover drugs for diseases where there are no existing therapies. This research will speed up the delivery of these medicines to patients and enable healthier, higher quality of life.

Public Health Research

05/03/2025

22/03/2024

TRE